NCT00346905 is a NA clinical trial of Enteryx in Gastroesophageal Reflux, sponsored by Beth Israel Deaconess Medical Center.

Who is sponsoring NCT00346905?

NCT00346905 is sponsored by Beth Israel Deaconess Medical Center.

What drugs are being tested in NCT00346905?

Interventions in NCT00346905: Enteryx.

What condition does NCT00346905 study?

NCT00346905 studies Gastroesophageal Reflux.

Is NCT00346905 still recruiting?

NCT00346905 is currently completed. Last updated 22 June 2017.

Are results published for NCT00346905?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-06-22 · How we verify

NCT00346905

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endoscopic Implantation of Enteryx for the Treatment of Gastroesophageal Reflux Disease (GERD): Post Market Study

Completed NA Results posted Last updated 22 June 2017

What this trial tests

NA trial testing Enteryx in Gastroesophageal Reflux in 16 participants. Completed in 1 February 2008.

Timeline

1 October 2003

Primary endpoint
1 February 2008

1 February 2008

Quick facts

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	1 October 2003
Primary completion	1 February 2008
Estimated completion	1 February 2008
Sites	1 location across United States

Drugs / interventions tested

Enteryx — full drug profile →

Conditions studied

Gastroesophageal Reflux — all drugs for Gastroesophageal Reflux →

Sponsor

Beth Israel Deaconess Medical Center

Who can join

Eligibility, any sex, with Gastroesophageal Reflux. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinically Significant Reduction of PPI Usage at 12, 24, and 36 Month Follow-ups Compared to Baseline in Both Singly Treated and Retreated Patients.
Time frame: 3 years either baseline to 12m, baseline to 24m, baseline to 36m
Clinically significant reduction of PPI usage is defined as either elimination of medication use or reduction in dosage of ≥50% as compared to baseline. The criterion for success is defined as more than half of patients demonstrating this degree of medication reduction.

Sponsor's own description

The study objective is to assess the long term safety and effectiveness of Enteryx device in commercial use. The long-term effects beyond one year of treatment with Enteryx have not been established.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gastroesophageal Reflux

Currently open trials in the same condition.

NCT07291700 — Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy · recruiting
NCT06255886 — Treatment of Gastroesophageal Reflux Disease in Infants · Phase 4 · recruiting
NCT06534359 — Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia · NA · recruiting
NCT06687603 — Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms · NA · recruiting
NCT06339801 — Role of Mucosal Impedance Measurement for the Diagnosis of Gastroesophageal Reflux Disease · recruiting

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

NCT07352657 — Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase) · NA · not yet recruiting
NCT07531602 — Effect of PEEP on Cardiac Function · NA · not yet recruiting
NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an · NA · not yet recruiting
NCT07277244 — Low-Intensity Mechanical Ventilation in the Operating Room: a Pilot Study · NA · enrolling by invitation
NCT06896474 — SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00346905 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beth Israel Deaconess Medical Center
Last refreshed: 22 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00346905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing